What pertussis mortality rates make maternal acellular pertussis immunization cost-effective in low- and middle-income countries? A decision analysis

Página do item simplificado
dc.creatorRussell, Louise B.
dc.creatorPentakota, Sri Ram
dc.creatorToscano, Cristiana Maria
dc.creatorCosgriff, Ben
dc.creatorSinha, Anushua
dc.date.accessioned2024-12-06T14:23:25Z
dc.date.available2024-12-06T14:23:25Z
dc.date.issued2016
dc.description.abstractBackground. Despite longstanding infant vaccination programs in low- and middle-income countries (LMICs), pertussis con tinues to cause deaths in the youngest infants. A maternal monovalent acellular pertussis (aP) vaccine, in development, could prevent many of these deaths. We estimated infant pertussis mortality rates at which maternal vaccination would be a cost-effective use of public health resources in LMICs. Methods. We developed a decision model to evaluate the cost-effectiveness of maternal aP immunization plus routine infant vaccination vs routine infant vaccination alone in Bangladesh, Nigeria, and Brazil. For a range of maternal aP vaccine prices, one-way sensitivity analyses identified the infant pertussis mortality rates required to make maternal immunization cost-effective by alternative benchmarks ($100, 0.5 gross domestic product [GDP] per capita, and GDP per capita per disability-adjusted life year [DALY]). Probabilistic sensitivity analysis provided uncertainty intervals for these mortality rates. Results. Infant pertussis mortality rates necessary to make maternal aP immunization cost-effective exceed the rates suggested by current evidence except at low vaccine prices and/or cost-effectiveness benchmarks at the high end of those considered in this report. For example, at a vaccine price of $0.50/dose, pertussis mortality would need to be 0.051 per 1000 infants in Bangladesh, and 0.018 per 1000 in Nigeria, to cost 0.5 per capita GDP per DALY. In Brazil, a middle-income country, at a vaccine price of $4/dose, infant pertussis mortality would need to be 0.043 per 1000 to cost 0.5 per capita GDP per DALY. Conclusions. For commonly used cost-effectiveness benchmarks, maternal aP immunization would be cost-effective in many LMICs only if the vaccine were offered at less than $1–$2/dose.
dc.identifier.citationRUSSELL, Louise B. et al. What pertussis mortality rates make maternal acellular pertussis immunization cost-effective in low- and middle-income countries? A decision analysis. Clinical Infectious Diseases, Oxford, v. 63, p. S227-S235, 2016. Suppl. 4. DOI: 10.1093/cid/ciw558. Disponível em: https://academic.oup.com/cid/article/63/suppl_4/S227/2526421?login=true. Acesso em: 4 dez. 2024.
dc.identifier.doi10.1093/cid/ciw558
dc.identifier.issn1058-4838
dc.identifier.issne- 1537-6591
dc.identifier.urihttp://repositorio.bc.ufg.br//handle/ri/26071
dc.language.isoeng
dc.publisher.countryEstados unidos
dc.publisher.departmentInstituto de Patologia Tropical e Saúde Pública - IPTSP (RMG)
dc.rightsAcesso Aberto
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectPertussis
dc.subjectMaternal immunization
dc.subjectMortality
dc.subjectCost-effectiveness
dc.subjectDecision analysis
dc.titleWhat pertussis mortality rates make maternal acellular pertussis immunization cost-effective in low- and middle-income countries? A decision analysis
dc.typeArtigo

Arquivos

Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
Artigo - Louise B. Russell - 2016.pdf
Tamanho:
466.3 KB
Formato:
Adobe Portable Document Format
Baixar
Licença do Pacote
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Baixar

Coleções

IPTSP - Artigos publicados em periódicos